These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20878823)

  • 1. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.
    Hoffmann-Röder A; Kaiser A; Wagner S; Gaidzik N; Kowalczyk D; Westerlind U; Gerlitzki B; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2010 Nov; 49(45):8498-503. PubMed ID: 20878823
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
    Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
    ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
    Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
    Gaidzik N; Westerlind U; Kunz H
    Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
    Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
    Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
    Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin.
    Dziadek S; Kowalczyk D; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7624-30. PubMed ID: 16247814
    [No Abstract]   [Full Text] [Related]  

  • 9. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
    Dziadek S; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
    [No Abstract]   [Full Text] [Related]  

  • 10. A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer.
    Glaffig M; Palitzsch B; Hartmann S; Schüll C; Nuhn L; Gerlitzki B; Schmitt E; Frey H; Kunz H
    Chemistry; 2014 Apr; 20(15):4232-6. PubMed ID: 24623572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.
    Kaiser A; Gaidzik N; Westerlind U; Kowalczyk D; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2009; 48(41):7551-5. PubMed ID: 19685547
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis and immunological evaluation of the unnatural β-linked mucin-1 Thomsen-Friedenreich conjugate.
    Wu X; McFall-Boegeman H; Rashidijahanabad Z; Liu K; Pett C; Yu J; Schorlemer M; Ramadan S; Behren S; Westerlind U; Huang X
    Org Biomol Chem; 2021 Mar; 19(11):2448-2455. PubMed ID: 33645601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.
    Cai H; Chen MS; Sun ZY; Zhao YF; Kunz H; Li YM
    Angew Chem Int Ed Engl; 2013 Jun; 52(23):6106-10. PubMed ID: 23616304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of MUC1-lipopeptide chimeras.
    Wilkinson BL; Malins LR; Chun CK; Payne RJ
    Chem Commun (Camb); 2010 Sep; 46(34):6249-51. PubMed ID: 20664875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of a MUC1-glycopeptide-BSA conjugate vaccine bearing the 3'-deoxy-3'-fluoro-Thomsen-Friedenreich antigen.
    Hoffmann-Röder A; Johannes M
    Chem Commun (Camb); 2011 Sep; 47(35):9903-5. PubMed ID: 21818465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
    Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
    Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen.
    Yang F; Zheng XJ; Huo CX; Wang Y; Zhang Y; Ye XS
    ACS Chem Biol; 2011 Mar; 6(3):252-9. PubMed ID: 21121644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
    Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.
    Stergiou N; Gaidzik N; Heimes AS; Dietzen S; Besenius P; Jäkel J; Brenner W; Schmidt M; Kunz H; Schmitt E
    Cancer Immunol Res; 2019 Jan; 7(1):113-122. PubMed ID: 30413430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.